The timing of GLP-1 administration may influence the tolerability of these symptoms, though this has not been definitively established in clinical trials
Insurance formulary coverage, manufacturer savings programs, and generic biosimilar pathways entering the market in 2026 further reduce cost and access barriers for most patients
However, fatigue accompanied by dizziness, pallor, abdominal pain, or low mood warrants prompt clinical review to exclude other causes
Yes, we have a cutting-edge device that scans your body using 3D, BIA, and BDA technology to provide accurate and consistent results for your fat, muscle, and water ratio
The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size